Research Article

Effects of Bevacizumab, an Anti Vascular Endothelial Growth Factor Monoclonal Antibody, on Kidney Function and Morphology

  • Neslihan Soysal Atile
  • Nezih Meydan
  • Muharrem Balkaya
  • İbrahim Meteoğlu
  • Cengiz Ünsal
  • Bülent Bilir

Received Date: 18.03.2016 Accepted Date: 25.03.2016 Namik Kemal Med J 2016;4(1):29-38


To constitute an experimental rat model by using human VEGF monoclonal antibody bevacizumab, for observation of renal side effects of this treatment.

Materials and Methods

Thirtysix adult female Wistar albino rats has been divided as two main groups: “3 days” and “21 days” . Each group has been divided in three; bevacizumab 10 mg/kg and 20 mg/kg were administered intravenously from the tail veins of the two subgroups and 1 mg/kg saline was administered to the third subgroup as control. Urine for 24 hours for detection of proteinuria and blood samples for detection of renal funtions were collected before, third day and 21st day of the drug administration and rats were sacrified at third and 21st days for pathological examination of kidneys.


Twenty four hours urine protein excretion, creatinin excretion and urine protein/creatinin ratio were demonstrated as significantly increased on the third day of the rats administered 10 mg/kg bevacizumab; however, any significant increase of proteinuria couldn’t be shown on the 21 days group rats administered neither 10 mg/kg or 20 mg/kg. Pathological examination of rats sacrified on third day demonstrate the significant increase of bowman capsule gap and interstitial inflamation as correlated with the dosage of the drug. The thickness of vessel wall was observed on the pathological examination of rats sacrified on 21st day.


It has been shown that bevacizumab administration of 10 mg/kg for three days is proper for constitution of an experimental rat model.

Keywords: human VEGF monoclonal antibody,bevacizumab,kidney